Latest Mirum Pharmaceuticals News & Updates

See the latest news and media coverage for Mirum Pharmaceuticals. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Mirum Pharmaceuticals

Rare disease biopharmaceutical company

mirumpharma.com
Headquarters
Foster City, United States
Founded year
2018
Company type
Public company
Number of employees
400–500

Last updated

Latest news about Mirum Pharmaceuticals

In short: Mirum Pharmaceuticals reported positive Phase 2b trial results for volixibat and brelovitug, boosting its liver disease pipeline and stock value.

Company announcements

  • Mirum Pharmaceuticals

    Mirum Pharmaceuticals reports Q1 2026 financial results

    Net product sales reach $159.9 million. Raises 2026 guidance to $660-680 million. Volixibat and brelovitug studies meet endpoints. Licenses zilurgisertib for FOP.

  • Mirum Pharmaceuticals

    Mirum announces VISTAS study meets primary endpoint

    Volixibat reduces pruritus significantly in PSC patients. Full results present at EASL Congress on May 30.

  • Mirum Pharmaceuticals

    Mirum Pharmaceuticals announces investor call

    The call on May 4, 2026, shares topline results from the VISTAS study of volixibat in PSC patients.

  • Mirum Pharmaceuticals

    Mirum Pharmaceuticals shares Q1 2026 results

    They host a webcast on May 6th at 1:30pm PT/4:30pm ET with a corporate update.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Mirum Pharmaceuticals

Track Mirum Pharmaceuticals and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Mirum Pharmaceuticals competitors & trending companies

Browse news for competitors to Mirum Pharmaceuticals and other trending companies.